-
Mashup Score: 12Modeling the acute mucosal toxicity to fractionated radiotherapy combined with the ATM inhibitor WSD0628 - 2 month(s) ago
Abstract. ATM inhibitors are being developed as radiosensitizers to improve the antitumor effects of radiotherapy, but ATM inhibition can also radiosensitize normal tissues. Therefore, understanding the elevated risk for normal tissue toxicities is critical for radiosensitizer development. This study focused on modeling the relationship between acute mucosal toxicity, radiation dose, fractionation schedule, and radiosensitizer exposure. The ATM inhibitor WSD0628 was combined with single or fractionated doses of radiation delivered to the oral cavity or esophagus of FVB mice. The potentiation by WSD0628 was quantified by a sensitizer enhancement ratio (SER), which describes the changes in radiation tolerance for radiation combined with WSD0628 relative to radiation-only regimens. WSD0628 profoundly enhanced radiation-induced acute oral and esophageal toxicities. For oral mucosal toxicity, the enhancement by WSD0628 with 3 fractions of radiation resulted in an SER ranging from 1.3 (0.25
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 32
PURPOSENRG-RTOG0617 demonstrated a detrimental effect of uniform high-dose radiation in stage III non–small cell lung cancer. NRG-RTOG1106/ECOG-ACRIN6697 (ClinicalTrials.gov identifier: NCT01507428), a randomized phase II trial, studied whether …
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
Another study where #radiotherapy dose escalation (PET guided 71 Gy vs 60 Gy) did not improve outcomes🤔 Disappointing Sample size feels small to find dose response IMO 2-yr local control of 55-60% clearly highlights need for treatment intensification⚠️ https://t.co/oEdglmcVsq
-
-
Mashup Score: 75Radiotherapy Improves Survival in NSCLC After Oligoprogression on Immunotherapy: A Cohort Study - 3 month(s) ago
The patterns of oligoprogression after first-line immune checkpoint inhibitors (ICIs) for metastatic NSCLC are yet to be well established. An increasing volume of data suggests that directed radiotherapy improves survival outcomes in patients with progression after ICIs.
Source: www.jtocrr.orgCategories: General Medicine News, Oncologists1Tweet-
Very intresting paper by Brown, @RadOncDoc_Gee @Eric73363938 et al, from 🇦🇺 They report outcomes in patients with oligoprogression following 1st line IO or ChemoIO 🚨Patients who receive #radiotherapy have better survival Paper link on @JTOonline : 🔗https://t.co/zISggmxpdA https://t.co/2eXnQrKgKY
-
-
Mashup Score: 36Stereotactic vs Hypofractionated Radiotherapy for Inoperable Stage I Non–Small Cell Lung Cancer - 4 month(s) ago
This randomized clinical trial examines whether stereotactic body radiotherapy improves local control compared with hypofractionated conventional radiotherapy.
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet-
📢Important trial SBRT 48/4, 60/8 v Hypofx 60/15 #radiotherapy in stage I NSCLC Well done👏 Several interpretations here What does "Severe toxic effects were limited" mean for patients? IMHO it supports 60Gy/3w for central NSCLC @DrAlexLouie @Dr_RayMak https://t.co/1JeMo08TtW
-
-
Mashup Score: 10New method could lower radiotherapy doses for some cancer patients - 5 month(s) ago
A special type of MRI scan where patients inhale 100% oxygen could result in lower radiotherapy doses for some cancer patients.
Source: www.icr.ac.ukCategories: General Medicine News, Oncologists1Tweet-
📰NEWS: Researchers at the ICR and @OfficialUoM have developed a new method that could lower the #radiotherapy doses for some cancer patients. Read more about their oxygen-enhanced magnetic resonance imaging ⤵️ https://t.co/I0DkUxu8zB
-
-
Mashup Score: 0
June 19, 2024 — RaySearch Laboratories AB announced a milestone in radiotherapy technology where RaySearch’s RayStation was used for the world’s first clinical treatment using OXRAY, a new treatment machine from Hitachi. The event took place on June 17 at Narita Memorial Hospital in Toyohashi, Japan.
Source: www.itnonline.comCategories: General Medicine News, General HCPsTweet-
.@RaySearch RayStation Used for First-Ever #Radiotherapy Treatment with Hitachi’s OXRAY system https://t.co/2CYQ5vGo19
-
-
Mashup Score: 231How public health services pay for radiotherapy in Europe: an ESTRO–HERO analysis of reimbursement - 9 month(s) ago
Reimbursement is a key factor in defining which resources are made available to ensure quality, efficiency, availability, and access to specific health-care interventions. This Policy Review assesses publicly funded radiotherapy reimbursement systems in Europe. We did a survey of the national societies of radiation oncology in Europe, focusing on the general features and global structure of the reimbursement system, the coverage scope, and level for typical indications. The annual expenditure covering radiotherapy in each country was also collected.
Source: www.thelancet.comCategories: General Medicine News, Oncologists2Tweet-
What I learned in 🇨🇱 today … $5mill = one #radiotherapy machine☢️, can treat 10k patients. $5mill = 135 patients worth of trastuzumab. 🧐 @TheLancetOncol - https://t.co/qyAG8X6Rdq “an essential pillar in multi-D oncology…an inexpensive modality” - 👏🏽 well said @TargetingCancer https://t.co/yxqNP9FEkA
-
-
Mashup Score: 18
Our findings suggests that systematic endoscopic mediastinal staging in patients with locally advanced or unresectable NSCLC is more accurate than PET alone in defining extent of mediastinal involvement. Standard guideline-recommended PET-based radiotherapy planning results in suboptimal tumour coverage. Our findings indicate that systematic endoscopic staging should be routinely performed in patients with locally advanced NSCLC being considered for radiotherapy to accurately inform radiation planning and treatment decision making in patients with locally advanced NSCLC.
Source: www.thelancet.comCategories: General Medicine News, Oncologists2Tweet-
3/ n=155, in 37% PET/EBUS was discordant – 12% ⬆️ disease, 25% ⬇️ disease extent. When upstaged with EBUS, missed lymph nodes get only ~10% of prescribed dose. We suggest use of systematic EBUS routinely before #radiotherapy. https://t.co/KCdkUIKk9Z
-
-
Mashup Score: 14Concurrent Olaparib and Radiation Therapy in Older Patients With Newly Diagnosed Glioblastoma: The Phase 1 Dose-Escalation PARADIGM Trial - 11 month(s) ago
Patients with glioblastoma who are older or have poor performance status (PS) experience particularly poor clinical outcomes. At the time of study ini…
Source: www.sciencedirect.comCategories: General Medicine News, Oncologists2Tweet-
Thanks @ECMC_UK for opportunity to discuss the many challenges of PARADIGM - biomarker driven randomised study of #radiotherapy + olaparib/placebo in older GBM pts 26 protocol amendments later we've published phase I and recruited 132 of 140 pts to ph II. https://t.co/TrVzHG5MHr https://t.co/3ReR5VTc73
-
-
Mashup Score: 55Consultant Clinical Scientist, Head of Service - Radiotherapy Physics :Beatson West of Scotland Cancer Centre / Gartnavel General Hospital - 12 month(s) ago
Salary: Band 8D (£94,345 – £98,384) NHS Greater Glasgow and Clyde is one of the largest healthcare systems in the UK employing around 40,000 staff in a wide range of clinical and non-clinical professions and job roles. We deliver acute hospital, primary, community and mental health care services to a population of over 1.15 million and a wider population of 2.2 million when our regional and national services are included. Applications are invited to join our dynamic, forward thinking and friendly team as
Source: apply.jobs.scot.nhs.ukCategories: General Medicine News, Oncologists2Tweet-
Fantastic opportunity to join our vibrant #radiotherapy community in Glasgow as Head of Radiotherapy Physics! https://t.co/D0vOXLHDjA Limitless R&D opportunities including @RadNetCRUKGla @UofGCancerSci @UofGPhysAstro @UofGEngineering Please repost! @ESTRO_RT @ASTRO_org
-
Nicely done mouse study by @MayoRadOnc on the radiobiology of combining a DDR inhibitor with #radiotherapy👍 @mct_aacr @DKirschMDPhD @xrtGenomics Modeling the acute mucosal toxicity to fractionated radiotherapy combined with the ATM inhibitor WSD0628 https://t.co/EdfNpDVZKV